Max Chat
Share chart Aerovate Therapeutics, Inc.
Extended chart
Simple chart
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Main settings
IPO date
2021-06-30
ISIN
US0080641071
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
2.56
Дивиденд ао
2.4
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | 34.68 | 1 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -67.03 | 0 |
| ROE | -74.91 | 0 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 2.56 | 6.4 |
| DSI | 1 | 10 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0056 | 10 |
| Debt/Ratio | 0.0052 | 10 |
| Debt/Equity | 0.051 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 682.25 | 10 |
| Yield EPS, % | -93.45 | 0 |
Dividends
| Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
| 2.56% | 2.4 | I кв. 2025 | 25.04.2025 | 29.04.2025 | 14.05.2025 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 93.8 $ | 0 $ | 0 $ | -97.14 % | 0 % | 0 % |
| Week | 93.8 $ | 0 $ | 0 $ | -97.14 % | 0 % | 0 % |
| Month | 93.8 $ | 2.68 $ | 93.8 $ | -97.14 % | 0 % | 0 % |
| Three month | 93.1 $ | 2.68 $ | 96.95 $ | -97.12 % | 0 % | 0 % |
| Half a year | 89.95 $ | 2.37 $ | 96.95 $ | -97.02 % | 0 % | 0 % |
| Year | 1.86 $ | 1.64 $ | 96.95 $ | +44.09 % | 0 % | 0 % |
| 3 years | 20.72 $ | 1.41 $ | 96.95 $ | -87.07 % | 0 % | 0 % |
| 5 years | 1.41 $ | 1.41 $ | 96.95 $ | +6 652.48 % | 0 % | 0 % |
| 10 years | 1.41 $ | 1.41 $ | 96.95 $ | +6 652.48 % | 0 % | 0 % |
| Year to date | 86.1 $ | 2.37 $ | 96.95 $ | -96.89 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| RA Capital Management, L.P. | 8 263 982 | 29.66 |
| Sofinnova Investments, Inc. | 3 758 686 | 13.49 |
| Tcg Crossover Management, Llc | 2 201 274 | 7.9 |
| Atlas Venture Life Science Advisors, LLC | 2 039 249 | 7.32 |
| Baker Brothers Advisors, LLC | 1 680 517 | 6.03 |
| Cormorant Asset Management, LP | 1 211 696 | 4.35 |
| Frazier Life Sciences Management, L.P. | 1 204 867 | 4.32 |
| Driehaus Capital Management, LLC | 1 058 209 | 3.8 |
| Great Point Partners LLC | 1 037 690 | 3.72 |
| Orbimed Advisors LLC. | 756 930 | 2.72 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Timothy P. Noyes M.B.A. | CEO & Director | 936.9k | 1962 (63 years) |
| Mr. George A. Eldridge | CFO & Treasurer | 658.6k | 1963 (62 years) |
| Dr. Marinus Verwijs Ph.D. | Chief Technical Officer | 439.88k | 1976 (49 years) |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, COO & Secretary | 435.5k | 1976 (49 years) |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer | 372.33k | 1960 (65 years) |
| Mr. Hunter Gillies M.D. | Chief Medical Officer | 512.74k | 1966 (59 years) |
| Mr. Timothy J. Pigot | Chief Commercial Officer | 584.6k | 1971 (54 years) |
| Ms. Donna Dea | Head of Regulatory Affairs | N/A | |
| Ms. Susan Fischer | Executive Vice President of Development Operations | N/A | |
| Mr. Stephen K. Yu | Senior Vice President of Quality | N/A |
About company
Address: United States, Waltham. MA, 930 Winter Street - Open in google maps, Open in yandex maps
Website: https://aerovatetx.com
Website: https://aerovatetx.com
